UBE2I and posterior cortical atrophy: To check whether UBC9 mediates PCa tumor growth in vivo, we treated RM-1 tumor–bearing C57BL/6J mice with the UBC9 inhibitor 2-D08 (10 mg/kg, every 3 days, intratumoral injection) or DMSO, the vehicle control (Figure 2A).